leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 00:17:05 - browse：22729

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： New CMS data security rules will hurt Medicare, Medicaid research

entertainment

WSS

Health officials lay out plans to cope with respiratory virus season

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

MD Anderson's Padmanee Sharma responds to research credit suit

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Can U.S. cancer drug shortages be fixed?

As obesity drug market grows, telehealth companies court payers

focus

leisure time

entertainment

Walensky prepares to leave CDC — and Congress — behind

A new drug could help frostbite victims avoid its ravages

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Psychedelics group wrestles with new pharma identity

Kellogg’s is going to war over Mexico’s nutrition label rules

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

DeSantis wants to import drugs. Biden’s FDA blasted his plan

leisure time

Former Pear Therapeutics executives start new VC firm

A new drug could help frostbite victims avoid its ravages

Obamacare plans could cover weight loss drugs

WATCH: Why do our ears pop?

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Congress may force more Covid

leisure time

entertainment

explore

explore